Key result
Indomethacin is linked to complete ductus closure in 67% of preterm infants without obvious dose-response correlation.
Why the study?
Pharmacokinetics, absolute bioavailability, and treatment outcomes of orogastric and intravenous indomethacin in very premature neonates with patent ductus arteriosus were not well characterized.
Does systemic exposure to varying plasma indomethacin concentrations correlate with ductus closure in very premature neonates with patent ductus arteriosus?
Population
90 preterm infants with patent ductus arteriosus, median gestational age 27 weeks, mean postnatal age 12 days, mean weight 1010 g
Comparison
Orogastric and/or intravenous indomethacin administration
Design
Population pharmacokinetic observational study
Authors
Loading...
May guide indomethacin dosing in preterm PDA; leaves open prospective outcome validation.
Observational (n=90)
Does systemic exposure to varying plasma indomethacin concentrations correlate with ductus closure in very premature neonates with patent ductus arteriosus?
The study found no obvious dose-response relationship between systemic indomethacin exposure and ductus closure in preterm infants, suggesting that individualized dosing based on target plasma concentrations is not supported.
Za’abi et al. (2007) conducted an observational in Patent ductus arteriosus (n=90). Orogastric and/or intravenous indomethacin was evaluated on Complete ductus closure. Orogastric and intravenous indomethacin resulted in complete ductus closure in 67% of preterm infants, with no obvious dose-response relationship between systemic exposure and closure.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: